Merrill retains Genmab at neutral

Genmab AS was retained at its neutral rating by Merrill Lynch analyst Erica Whittaker as the company's second-quarter 2006 financial results were in line with the analyst's expectations. With Serono's phase 3 data for HuMax-CD4 not available until the first half of 2007, Merrill does not see a launch until 2008. Therefore, the analyst moved Genmab revenues under the CD4 licensing deal out one year to 2008. According to the analyst, Genmab has one of the most attractive product pipelines in European biotech. Shares of the Copenhagen, Denmark, biotechnology company were up Dkr 7.50, or 3.56%, at Dkr 218.00 on volume of 385,537 shares versus the three-month running average of 114,592 shares. (Copenhagen: GEN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.